[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360663-105":59,"doc-detail-360663-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-review-of-recent-advances-in-chimeric-antigen-receptor-car-t-cell-therapy-for-hepatocellular-carcinoma","A Review of Recent Advances in Chimeric Antigen Receptor (CAR) T-Cell Therapy for Hepatocellular Carcinoma","","Hepatocellular carcinoma (HCC) remains the most common primary liver cancer and a major global cause of cancer-related death, especially where chronic viral hepatitis, cirrhosis, alcohol-related liver disease, and metabolic dysfunction-associated steatotic liver disease are prevalent. Although multiple modalities and systemic agents have improved care, outcomes for advanced HCC are still unsatisfactory. The review analyzes CAR T-cell adoptive immunotherapy, summarizes target-based clinical studies, and discusses how CAR structural evolution and tumor microenvironment barriers affect therapeutic development.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-review-of-recent-advances-in-chimeric-antigen-receptor-car-t-cell-therapy-for-hepatocellular-carcinoma/360663/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-review-of-recent-advances-in-chimeric-antigen-receptor-car-t-cell-therapy-for-hepatocellular-carcinoma/360663.png","ImageObject",300,407,{"name":92,"@type":93},"4398046744996","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is CAR T-cell therapy still developing for hepatocellular carcinoma?","Question",{"text":112,"@type":113},"Its progress is limited by tumor heterogeneity, antigen escape, restricted T-cell trafficking, and an immunosuppressive tumor microenvironment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which HCC-associated antigen targets are discussed in the review?",{"text":117,"@type":113},"The review covers targets including GPC3, CEA, AFP, CD133, EGFRvIII, B7H3, MUC1, NKG2DL, PD-L1/c-Met, CD147, CD44, and EpCAM.",{"name":119,"@type":110,"acceptedAnswer":120},"What does the article focus on regarding CAR-T-cell therapy development?",{"text":121,"@type":113},"It provides target-oriented synthesis, summarizes registered clinical studies by antigen target and trial characteristics, and discusses how CAR structural evolution may influence therapeutic development.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360663,1790176336,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":66,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":133,"file_id":134,"file_url":135,"file_type":136,"file_size":137,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":138,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},4398046744996,"REVIEW ARTICLES  \ne-ISSN 1643-3750  \n© Med Sci Monit, 2026; 32: e953528 DOI: 10. 12659/MSM.953528  \nReceived: 2026.03.24  \nAccepted: 2026.06.01  \nAvailable online: 2026.06.11  \nPublished: 2026.06.23  \nAuthors’ Contribution: Study Design A  \nData Collection B Statistical Analysis C Data Interpretation D Manuscript Preparation E Literature Search F Funds Collection G  \nABE  \nBCE  \nAC  \nDF  \nBCD  \nDF  \nACFG  \nCorresponding Author: Financial support:  \nConflict of interest:  \n1 1  \n1 1  \n1 2  \n2  \nA Review of Recent Advances in Chimeric Antigen Receptor (CAR) T-Cell Therapy for Hepatocellular Carcinoma  \nXiaopan Lv* Xuemei Chen* Yuxin Ge Guifei Si Yuquan Li Xiuping Li Xuemin Yuan  \n1 School of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong, PR China  \n2 Department of Gastroenterology, Linyi People’s Hospital, Linyi, Shandong, PR China  \n* Xiaopan Lv and Xuemei Chen contributed equally to this work and share first authorship  \nXuemin Yuan, Phone: +86 18266759800, e-mail: [lyxhyxm@163.com](lyxhyxm@163.com)  \nThis work was supported by grants from the general project of the Development Fund of the Affiliated Hospital of Xuzhou Medical University (XYFM2021032), Linyi Key R&D Program (2022YX0028)  \nNone declared  \nHepatocellular carcinoma (HCC) is the most common form of primary liver cancer and poses a major global health burden. It remains a leading cause of cancer-related death worldwide, with persistently high incidence and mortality in regions affected by chronic viral hepatitis, cirrhosis, alcohol-related liver disease, and metabolic dysfunction-associated steatotic liver disease.  \nAlthough surgical resection, liver transplantation, locoregional therapies, molecular targeted agents, and immune checkpoint inhibitors have improved treatment options, outcomes for advanced HCC remain unsatisfactory. Chimeric antigen receptor (CAR) T-cell therapy is an adoptive cellular immunotherapy in which T lymphocytes are genetically engineered to recognize tumor-associated antigens and eliminate malignant cells. CAR-T-cell therapy has achieved major clinical success in hematologic malignancies, but its application in HCCis still developing because of tumor heterogeneity, antigen escape, limited T-cell trafficking, and an immunosuppressive tumor microenvironment. Recent studies have investigated several HCC-associated targets, including glypican-3 (GPC3), carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), CD133, epidermal growth factor receptor variant III (EGFRvIII), B7 homolog 3 (B7H3), mucin 1 (MUC1), natural killer group 2 member D ligand (NKG2DL), programmed death-ligand 1 (PD-L1)/c-Met, CD147, CD44, and epithelial cell adhesion molecule (EpCAM). This article provides a target-oriented synthesis of HCC-related CAR-T-cell therapy, summarizes registered clinical studies according to antigen target, CAR design, trial phase, administration route, and available outcomes, and discusses how CAR structural evolution may influence therapeutic development in HCC. This article aims to review recent advances in CAR-T-cell therapy for hepatocellular carcinoma.  \nKeywords: Carcinoma, Hepatocellular • Receptors, Chimeric Antigen • T-Lymphocytes •  \nImmunotherapy, Adoptive • Review  \nFull-text PDF: [https://www.medscimonit.com/abstract/index/idArt/953528](https://www.medscimonit.com/abstract/index/idArt/953528)  \n2139  1  2  94  \nPublisher’s note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher  \nThis work is licensed under Creative Commons AttributionNonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)  \ne953528-1  \nIndexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System][ISI Journals Master ","cbCaieFt47v2OOQi","https://ap.wps.com/l/cbCaieFt47v2OOQi","pdf",1268230,11,"English","# Introduction\n# CAR-T-cell therapy for HCC: rationale and challenges\n# HCC-associated CAR targets\n# Summary of registered clinical studies\n## By antigen target, CAR design, trial phase, and route\n# CAR structural evolution and future directions","[{\"question\":\"Why is CAR T-cell therapy still developing for hepatocellular carcinoma?\",\"answer\":\"Its progress is limited by tumor heterogeneity, antigen escape, restricted T-cell trafficking, and an immunosuppressive tumor microenvironment.\"},{\"question\":\"Which HCC-associated antigen targets are discussed in the review?\",\"answer\":\"The review covers targets including GPC3, CEA, AFP, CD133, EGFRvIII, B7H3, MUC1, NKG2DL, PD-L1/c-Met, CD147, CD44, and EpCAM.\"},{\"question\":\"What does the article focus on regarding CAR-T-cell therapy development?\",\"answer\":\"It provides target-oriented synthesis, summarizes registered clinical studies by antigen target and trial characteristics, and discusses how CAR structural evolution may influence therapeutic development.\"}]","A Review of Recent Advances in Chimeric Antigen Receptor (CAR) T-Cell Therapy for Hepatocellular Carcinoma | PDF",1790140981,28,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/95bd2a4ac0d7d88aec664a8470d1eb32.webp",983,1376,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8a092d51c2dabc358af0b6b101ba45e0.webp",982,1374,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4ef5569c23e17312e42b84489f937213.webp",981,1373,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9611b366a212d240838541af48eeb80e.webp",980,1372]